# UK Gout Market > UK Gout Market Research Report: Size, Share, Trend Analysis By Treatment and Diagnosis (Diagnosis, Treatment, NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, Others), By Applications (Acute Gout, Chronic Gout) andBy End Users (Hospitals & Clinics, Specialty Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 11.75% - **2024:** $ 212.46 Million - **2025:** $ 237.43 Million - **2035:** $ 720.9 Million - **Key Players:** AstraZeneca (GB), Novartis (CH), Pfizer (US), Teva Pharmaceutical Industries (IL), Horizon Therapeutics (IE), AbbVie (US), Amgen (US), Sanofi (FR) **Report ID:** MRFR/HC/47501-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-gout-market-49251 --- ## Market Summary # **UK Gout Market Overview** As per MRFR analysis, the UK Gout Market Size was estimated at 228.15 (USD Million) in 2023.The UK Gout Market Industry is expected to grow from 255.15(USD Million) in 2024 to 869.62 (USD Million) by 2035. The UK Gout Market CAGR (growth rate) is expected to be around 11.792% during the forecast period (2025 - 2035). ### **Key UK Gout Market Trends Highlighted** The UK Gout Market is undergoing vast changes because there is a higher occurrence of gout in the population. The condition is receiving more attention due to sociodemographic and modern campaign and diagnostic tool progress, which helps identify and manage gout better. One of the noteworthy changes is the addition of personalized management strategies that include medications, lifestyle alterations, and patient-specific needs. This is part of a larger initiative in the UK healthcare system toward improved health outcomes and increased patient-centered care. The need for efficient treatment for gout is also exacerbated by the growing population of elderly people in the UK who suffer from chronic ailments. The development of new therapies and emerging medications, especially biologics, offer novel avenues for patient care. The UK National Health Service has been supportive of better gout management which has steered efforts toward innovative solutions and therapies to turn patient sufferings into their comfort. There is also increasing focus on preventive approaches such as dietary changes and learning about the dangers of foods high in purines that are commonly associated with gout flares. The professionals in the UK are encouraging patients to shift toward healthier living as well as consider other treatment modalities. An increase in awareness, the improvement of treatment methods, and the incorporation of other aspects of medicine into healthcare results in a big gap in the market for existing and new competitors in the UK Gout Market that need to be filled with solutions to cl adequately improve management of this widespread condition. ### **UK Gout Market Drivers** #### **Increase in Gout Incidence Rates** The UK Gout Market Industry is experiencing significant growth, primarily driven by the increasing incidence of gout among the population. Recent statistics indicate that approximately 2 million individuals in the UK are currently affected by gout, a number which is expected to rise due to lifestyle factors such as obesity, high purine diets, and sedentary habits. According to Public Health England, the prevalence of gout in adults has risen by around 26% over the last decade. This surge in cases has heightened awareness of gout-related complications and has prompted healthcare providers to seek effective treatments, thereby driving demand within the UK Gout Market. Moreover, organizations such as the National Health Service (NHS) have been actively promoting better patient management practices and awareness campaigns, leading to increased diagnoses and treatment options available to patients, further boosting market growth. #### **Advancements in Treatment Options** The UK Gout Market Industry is benefiting from advancements in treatment options, significantly enhancing patient outcomes. Over the past several years, pharmaceutical companies have developed novel therapies and medications specifically targeting hyperuricemia, which is the primary cause of gout. For instance, recent approvals of drugs like Febuxostat and Lesinurad have offered patients new, effective ways to manage their condition. These advancements in treatments not only improve the quality of life for those suffering from gout but also align with the initiatives set forth by the National Institute for Health and Care Excellence (NICE), which aims to ensure that patients have access to the latest evidence-based treatments. The continuous focus on Research and Development by leading organizations in the pharmaceutical sector ensures that the UK Gout Market continues to evolve and adapt to patient needs. #### **Growing Public Health Awareness** Public health awareness regarding gout and its management has significantly increased in the UK, serving as a crucial driver for the UK Gout Market Industry. Public Health England has initiated programs to educate the population about gout, its symptoms, risk factors, and effective management strategies. Studies show that public awareness campaigns have resulted in almost 30% of the general public recognizing the symptoms of gout compared to previous years. This rising awareness has fostered early diagnosis and treatment, positively impacting patient care and outcomes, which in turn fuels the demand for gout-related pharmaceutical products and services. As healthcare systems emphasize preventive measures and patient education, the market is positioned for continued growth. ## **UK Gout Market Segment Insights** ### **Gout Market Treatment and Diagnosis Insights** The Treatment and Diagnosis segment of the UK Gout Market is a crucial area as it encompasses various methodologies and therapeutics essential for effective disease management. This segment is characterized by an increasing prevalence of gout, particularly in the UK, where lifestyle factors and dietary habits contribute to its rise among the population. The market growth is driven by the need for accurate and expedient diagnosis, coupled with advanced treatment options. The diagnosis aspect focuses on utilizing state-of-the-art imaging techniques and laboratory tests that facilitate prompt identification of gout, which is instrumental in preventing severe complications associated with late diagnosis. Several treatment options feature prominently in the market, highlighting the diverse approaches available to address gout flares and to manage chronic conditions. Non-steroidal anti-inflammatory drugs (NSAIDs) are a dominant treatment modality, often preferred for their efficacy in mitigating pain and inflammation during acute gout attacks. Furthermore, corticosteroids and colchicine constitute vital therapeutic alternatives when NSAIDs are contraindicated or ineffective, ensuring that patients have access to relief options tailored to their individual responses. Urate-lowering agents represent another critical component of the treatment paradigm aimed at controlling hyperuricemia, a primary factor in gout pathogenesis, leading to long-term disease management and preventing future flare-ups. The strategic positioning of these agents in treatment protocols speaks to their importance in the ongoing efforts to modify disease progression and improve patient outcomes. Additionally, the market is witnessing an influx of novel therapies, as companies invest in Research and Development to introduce innovative drugs that could revolutionize gout management. Overall, the Treatment and Diagnosis segment reflects a robust landscape that is constantly evolving, driven by research advancements, regulatory endorsements for new drugs, and a growing awareness of gout management among healthcare professionals and patients alike. The segment showcases a blend of traditional and technological advanced modalities, demonstrating its capacity to adapt to the rising needs of the UK population, thereby influencing market statistics positively. This dynamic landscape not only highlights the challenges faced in managing gout but also presents significant opportunities for stakeholders in the UK Gout Market to enhance treatment offerings and improve patient care. ### **Gout Market Application Insights** The Application segment of the UK Gout Market encompasses critical categories such as Acute Gout and Chronic Gout, highlighting the diverse manifestations of this prevalent condition. With gout being a significant concern for the UK population, the market spotlight is increasingly directed towards effective treatment modalities tailored for both acute episodes and chronic management. Acute Gout typically features sudden onset attacks, characterized by intense pain, necessitating prompt intervention, which drives the demand for fast-acting therapeutic solutions. On the other hand, Chronic Gout requires ongoing management strategies to mitigate flare-ups and prevent complications, contributing to its notable share in the market landscape. The growing awareness about lifestyle factors influencing gout prevalence combined with the aging population accentuates the need for targeted treatments. Additionally, advancements in therapeutic options, including innovative medications and lifestyle modification programs, create opportunities for growth within this segment. As a result, this Application segment holds a significant place in the overall UK Gout Market landscape, underlining the importance of strategic approaches in addressing the unique challenges posed by both acute and chronic forms of the disease. ### **Gout Market End User Insights** The End User segment of the UK Gout Market is critical in delineating how treatments and services are distributed among various healthcare settings. Hospitals and Clinics play a pivotal role in managing gout, providing immediate care and specialized treatment options that cater to a large patient demographic. Specialty Centers are significant as they offer focused care, facilitating advanced therapies and targeted approaches for gout management, thereby attracting patients looking for expert guidance. Additionally, the 'Others' segment encapsulates alternative treatment settings, which are gaining traction among patients seeking complementary therapies. There is a rising trend towards integrated care models, combining various treatment modalities across these End User types, which reflects the growing recognition of gout as a major public health concern in the UK. This market is driven by an increasing prevalence of gout, particularly within aging populations, and a heightened awareness of the importance of prompt treatment to avoid complications. As the UK government emphasizes healthcare access and quality, investment in specialized facilities is likely to foster a more developed market landscape. The UK Gout Market statistics demonstrate that addressing the diverse needs within the End User categories will be crucial in improving patient outcomes and enhancing overall market growth. ## **UK Gout Market Key Players and Competitive Insights** The UK[Gout Market](../../../reports/gout-market-5909) is characterized by a competitive landscape where various players strive to develop effective treatments and address the unique challenges associated with gout management. Companies operating within this sector are focused on offering innovative therapies to alleviate symptomatology and improve the quality of life for patients suffering from this form of arthritis. The competitive insights reveal a trend toward collaborations, mergers, and innovative product development aimed at capturing market share while responding to the growing patient population and increasing awareness of gout. Enhanced distribution strategies, coupled with significant investments in research and development, enable firms to better position themselves in this niche market, ultimately leading to heightened competition among key stakeholders. ### **United BioSource** United BioSource has established a strong presence within the UK Gout Market, primarily attributed to its comprehensive understanding of patient needs and effective management strategies for gout treatment. The company's expertise lies in delivering critical data and insights that drive informed business decisions. United BioSource's strengths include its robust network within the healthcare ecosystem and the ability to engage in patient-focused services that enhance treatment accessibility and adherence. The company excels in navigating regulatory challenges and collaborating with stakeholders to deliver value-added services, making it a formidable player in the UK landscape of gout management. Their commitment to facilitating clinical research and real-world evidence generation further complements their strength within the market. ### **Genzyme** Genzyme, recognized for its significant contributions to the UK Gout Market, offers a diverse portfolio of products and services aimed at optimizing the management of gout among patients. Key products from Genzyme have focused on addressing both acute and chronic phases of the condition, leveraging advancements in biotechnology to ensure effective treatment outcomes. The company's strong market presence is sustained by its strategic approach to partnerships and alliances that enhance its capabilities in drug development and patient care initiatives. Furthermore, Genzyme benefits from its history of mergers and acquisitions that catalyze growth and drive innovation, allowing it to introduce cutting-edge therapies tailored to the UK market. The emphasis on research and development, in conjunction with their commitment to improving patient outcomes, solidifies Genzyme's stature as a leading entity in the UK's gout treatment sector. ### **Key Companies in the UK Gout Market Include** ## **UK Gout Market Industry Developments** The UK Gout Market has witnessed significant developments recently, with companies like AstraZeneca, Novartis, and GSK investing heavily in Research and Development to address the increasing prevalence of gout. Recent data indicates a rising market valuation for firms engaged in gout treatments, driven by higher patient demand and improved treatment options. Notably, Horizon Therapeutics expanded its reach in September 2023 by acquiring a promising drug candidate, showcasing its commitment to addressing gout. Additionally, AbbVie has been strengthening its position through strategic partnerships and product launches aimed at enhancing patient outcomes. In terms of market dynamics, an increase in awareness and diagnosis of gout over the past few years has led to more targeted therapies being introduced. Between late 2021 and early 2023, the focus shifted towards combining existing therapies with novel agents, aiming to provide better management for patients. UK health authorities continue to promote education around gout, further supporting the need for innovative treatments. The competitive landscape remains robust as companies like Merck and Pfizer also vie for market share, continually reshaping the therapeutic approaches available to healthcare providers in the UK. ## **UK Gout Market Segmentation Insights** ### **Gout Market Treatment and Diagnosis Outlook** ### **Gout Market Application Outlook** ### **Gout Market End User Outlook** - Hospitals & Clinics - Specialty Centers - Others ## Market Drivers ### Increasing Prevalence of Gout The rising incidence of gout in the UK is a notable driver for the gout market. Recent data indicates that approximately 1.5 million individuals in the UK are affected by this condition, with a significant increase in cases observed over the past decade. This surge can be attributed to lifestyle factors such as dietary habits and obesity, which are known to exacerbate the condition. As the population ages, the prevalence of gout is expected to rise further, thereby increasing the demand for effective treatments and management options. Consequently, pharmaceutical companies and healthcare providers are likely to focus on developing targeted therapies, which could lead to substantial growth in the gout market. ### Rising Healthcare Expenditure The increasing healthcare expenditure in the UK is a significant driver for the gout market. As the government allocates more resources to healthcare, there is a corresponding rise in spending on treatments for chronic conditions, including gout. In 2025, healthcare spending is expected to reach £200 billion, with a notable portion directed towards managing gout and related diseases. This trend indicates a growing recognition of the economic burden posed by gout, prompting healthcare providers to invest in more effective treatment options. Consequently, the gout market is likely to benefit from enhanced funding and resources, facilitating the development of innovative therapies. ### Advancements in Pharmaceutical Research Ongoing advancements in pharmaceutical research are propelling the gout market forward. The development of novel medications, including urate-lowering therapies and anti-inflammatory agents, has shown promise in managing gout symptoms effectively. Recent studies suggest that the market for gout medications in the UK is projected to reach £500 million by 2026, reflecting a compound annual growth rate (CAGR) of approximately 6%. This growth is driven by the introduction of innovative drugs that offer improved efficacy and safety profiles. As research continues to evolve, the gout market is likely to witness an influx of new treatment options, catering to the diverse needs of patients. ### Growing Demand for Personalized Medicine The shift towards personalized medicine is reshaping the gout market landscape in the UK. Patients increasingly seek tailored treatment plans that consider their unique genetic and lifestyle factors. This trend is supported by advancements in genetic research and biomarker identification, which enable healthcare providers to offer more effective and individualized therapies. As a result, pharmaceutical companies are likely to invest in developing personalized treatment options for gout, which could enhance patient adherence and outcomes. The growing emphasis on personalized medicine may lead to a transformation in the gout market, fostering innovation and improving overall patient care. ### Government Initiatives and Healthcare Policies Government initiatives aimed at improving healthcare access and quality are influencing the gout market in the UK. Policies promoting early diagnosis and treatment of gout are essential in reducing the long-term burden of the disease. The National Health Service (NHS) has implemented guidelines that encourage healthcare professionals to screen at-risk populations, thereby facilitating timely intervention. Such initiatives not only enhance patient outcomes but also contribute to the overall growth of the gout market. Increased funding for research and public health campaigns further supports awareness and education, which are crucial for effective disease management. ## Future Outlook The [Gout Market](https://www.marketresearchfuture.com/reports/gout-market-5909) is projected to grow at 11.75% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising awareness. **New opportunities:** - Development of personalized medicine for gout management - Expansion of telehealth services for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection By 2035, the gout market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Treatment: Urate-Lowering Agents (Largest) vs. NSAIDs (Fastest-Growing) In the UK gout market, the treatment segment is dominated by Urate-Lowering Agents, which command the largest market share among treatment options available. Following this, NSAIDs hold a significant position, being favored for their effective pain management capabilities. Colchicine and corticosteroids also play notable roles, but their shares are comparatively less prominent, with 'Others' encapsulating less common treatment choices. Growth trends within the treatment segment indicate a shift towards Urate-Lowering Agents as awareness about chronic gout management increases. This segment's growth is primarily driven by enhanced patient compliance and ongoing research yielding more efficient treatment options. Conversely, NSAIDs are emerging as the fastest-growing category, due to the increase in acute gout attacks and a corresponding rise in prescription rates, reflecting an evolving treatment landscape. Urate-Lowering Agents (Dominant) vs. NSAIDs (Emerging) Urate-Lowering Agents are acknowledged as the dominant force within the treatment segment due to their efficacy in managing uric acid levels and preventing flares. Their widespread acceptance among healthcare professionals underscores their critical role in long-term gout management. Meanwhile, NSAIDs are categorized as an emerging treatment, gaining traction as acute pain management solutions, particularly favored for quick relief during gout attacks. The versatility and accessibility of NSAIDs make them a popular choice, while ongoing developments aim to enhance their safety profiles, contributing to their increasing utilization in the UK gout market. ### By Application: Acute Gout (Largest) vs. Chronic Gout (Fastest-Growing) In the UK gout market, Acute Gout stands as the largest segment, capturing a significant share of the market. This segment has traditionally been the main focus for treatment options, leading to higher visibility among healthcare providers and patients alike. In contrast, Chronic Gout, while smaller in current market share, is gaining traction due to the increasing awareness around long-term management and the benefits of preventative strategies, which are becoming more prioritized in healthcare settings. Growth trends indicate a robust shift towards Chronic Gout, which is recognized as the fastest-growing segment. The rising prevalence of lifestyle-related risk factors and comorbidities prompts a more proactive management approach. Furthermore, advancements in pharmaceutical solutions and treatment protocols for Chronic Gout are expected to attract more patients, fostering greater acceptance and boosting growth rates within this segment. Gout Type: Acute Gout (Dominant) vs. Chronic Gout (Emerging) Acute Gout is positioned as the dominant segment due to its immediate treatment needs for sudden flare-ups, making it a primary focus within the UK gout market. The prevalence of acute episodes encourages ongoing investment in effective pain relief medications and care strategies. Meanwhile, Chronic Gout is emerging as an increasingly significant segment due to the long-term nature of the condition, necessitating a shift in treatment paradigms to encompass preventive care. As healthcare systems evolve, more emphasis is placed on managing chronic conditions, leading to increased research and product development for comprehensive care solutions, thereby enhancing its market appeal. ### By End User: Hospitals & Clinics (Largest) vs. Specialty Centers (Fastest-Growing) In the UK gout market, the 'End User' segment sees a significant distribution of market share between Hospitals & Clinics and Specialty Centers. Hospitals & Clinics command a dominant position due to their extensive infrastructure, offering a wide range of treatment options for gout patients. Meanwhile, Specialty Centers, while smaller in share, are rapidly gaining traction as they cater to specific patient needs with tailored services. Recent trends indicate robust growth within the Specialty Centers segment, fueled by an increasing patient preference for specialized care and advanced treatment protocols. The emergence of new therapies and technologies in managing gout is perpetuating this growth. Additionally, rising awareness about gout and its complications is driving more patients towards facilities that specialize in treating this condition, setting the stage for continued expansion in this segment. Hospitals & Clinics (Dominant) vs. Specialty Centers (Emerging) Hospitals & Clinics are recognized as the dominant end-user segment within the UK gout market, primarily due to their ability to provide comprehensive care along with a full spectrum of services ranging from diagnosis to advanced treatments. Their established reputation and resources enable them to manage complex gout cases effectively. On the other hand, Specialty Centers represent an emerging segment that is poised for growth, focusing on innovative treatment approaches and patient-centered care. These centers often offer personalized treatment plans and have the advantage of specialized staff trained in gout management. As the demand for specialized care increases, Specialty Centers are expected to carve out a larger share of the market, propelled by their unique value proposition in enhancing patient outcomes. ## Competitive Benchmarking The gout market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AstraZeneca (GB), Novartis (CH), and Pfizer (US) are actively shaping the market dynamics through their distinct operational strategies. AstraZeneca (GB) emphasizes innovation in drug development, particularly in biologics, while Novartis (CH) focuses on expanding its portfolio through strategic acquisitions and partnerships. Pfizer (US), on the other hand, is leveraging its extensive distribution network to enhance market penetration, thereby influencing the competitive environment significantly.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like AstraZeneca (GB) and Pfizer (US) suggests a trend towards consolidation, as these firms seek to strengthen their market positions through strategic collaborations and resource sharing. In October Novartis (CH) announced a partnership with a leading biotechnology firm to co-develop a novel gout treatment aimed at improving patient outcomes. This strategic move is likely to enhance Novartis's competitive edge by diversifying its product offerings and tapping into innovative research capabilities. Such collaborations may also accelerate the development timeline for new therapies, positioning Novartis favorably in a rapidly evolving market. In September Pfizer (US) launched a digital health initiative aimed at improving patient adherence to gout medications through mobile applications. This initiative underscores Pfizer's commitment to integrating technology into healthcare solutions, potentially leading to better patient engagement and outcomes. By harnessing digital tools, Pfizer may not only enhance its product value proposition but also strengthen its relationship with healthcare providers and patients alike. In August AstraZeneca (GB) expanded its manufacturing capabilities in the UK to support the production of its gout therapies. This expansion reflects AstraZeneca's strategic focus on localizing production to meet growing demand while ensuring supply chain reliability. Such investments are indicative of a broader trend where companies prioritize operational efficiency and responsiveness to market needs. As of November the competitive trends in the gout market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are becoming pivotal in shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative therapies, and robust supply chain management. This shift may ultimately redefine how companies position themselves in the market, emphasizing the importance of agility and responsiveness to patient needs. ## Recent News & Developments The UK Gout Market has witnessed significant developments recently, with companies like AstraZeneca, Novartis, and GSK investing heavily in Research and Development to address the increasing prevalence of gout. Recent data indicates a rising market valuation for firms engaged in gout treatments, driven by higher patient demand and improved treatment options. Notably, Horizon Therapeutics expanded its reach in September 2023 by acquiring a promising drug candidate, showcasing its commitment to addressing gout. Additionally, AbbVie has been strengthening its position through strategic partnerships and product launches aimed at enhancing patient outcomes. In terms of market dynamics, an increase in awareness and diagnosis of gout over the past few years has led to more targeted therapies being introduced. Between late 2021 and early 2023, the focus shifted towards combining existing therapies with novel agents, aiming to provide better management for patients. UK health authorities continue to promote education around gout, further supporting the need for innovative treatments. The competitive landscape remains robust as companies like Merck and Pfizer also vie for market share, continually reshaping the therapeutic approaches available to healthcare providers in the UK. ## Report Scope | MARKET SIZE 2024 | 212.46(USD Million) | | --- | --- | | MARKET SIZE 2025 | 237.43(USD Million) | | MARKET SIZE 2035 | 720.9(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.75% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AstraZeneca (GB), Novartis (CH), Pfizer (US), Teva Pharmaceutical Industries (IL), Horizon Therapeutics (IE), AbbVie (US), Amgen (US), Sanofi (FR) | | Segments Covered | Treatment, Application, End User | | Key Market Opportunities | Emerging therapies and personalized medicine approaches present growth opportunities in the gout market. | | Key Market Dynamics | Rising prevalence of gout drives demand for innovative therapies and personalized treatment approaches in the UK. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the overall market valuation of the UK gout market in 2024?** A: The overall market valuation was 212.46 $ Million in 2024. **Q: What is the projected market valuation for the UK gout market by 2035?** A: The projected valuation for 2035 is 720.9 $ Million. **Q: What is the expected CAGR for the UK gout market during the forecast period 2025 - 2035?** A: The expected CAGR for the UK gout market during the forecast period 2025 - 2035 is 11.75 %. **Q: Which companies are considered key players in the UK gout market?** A: Key players in the market include AstraZeneca (GB), Novartis (CH), Pfizer (US), Teva Pharmaceutical Industries (IL), Horizon Therapeutics (IE), AbbVie (US), Amgen (US), and Sanofi (FR). **Q: What are the main treatment segments in the UK gout market?** A: The main treatment segments include NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, and Others. **Q: What was the valuation range for Urate-Lowering Agents in 2024?** A: The valuation range for Urate-Lowering Agents was 100.0 to 350.0 $ Million in 2024. **Q: How does the market for Acute Gout compare to Chronic Gout in terms of valuation?** A: In 2024, the market for Acute Gout was valued between 85.0 and 300.0 $ Million, while Chronic Gout was valued between 127.46 and 420.9 $ Million. **Q: What are the end-user segments in the UK gout market?** A: End-user segments include Hospitals & Clinics, Specialty Centers, and Others. **Q: What was the valuation range for Hospitals & Clinics in 2024?** A: The valuation range for Hospitals & Clinics was 85.0 to 300.0 $ Million in 2024. **Q: What is the potential growth outlook for the UK gout market?** A: The market appears poised for growth, with a projected valuation increase to 720.9 $ Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-gout-market-49251*